C12N 2770/24011
Flaviviridae
C12N2770/24011 (Flaviviridae) appears on 1,815 US grants and 2,352 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,815
- Published applications
- 2,352
- Assignees
- 971
- Inventors
- 3,923
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 3 | 0 |
| 1985 | 3 | 0 |
| 1986 | 2 | 0 |
| 1987 | 4 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 8 | 0 |
| 1994 | 11 | 0 |
| 1995 | 9 | 0 |
| 1996 | 18 | 0 |
| 1997 | 24 | 0 |
| 1998 | 61 | 0 |
| 1999 | 65 | 0 |
| 2000 | 58 | 0 |
| 2001 | 63 | 5 |
| 2002 | 37 | 61 |
| 2003 | 62 | 119 |
| 2004 | 35 | 92 |
| 2005 | 41 | 95 |
| 2006 | 51 | 90 |
| 2007 | 52 | 93 |
| 2008 | 61 | 96 |
| 2009 | 48 | 130 |
| 2010 | 63 | 145 |
| 2011 | 63 | 136 |
| 2012 | 69 | 107 |
| 2013 | 67 | 78 |
| 2014 | 86 | 94 |
| 2015 | 68 | 79 |
| 2016 | 61 | 88 |
| 2017 | 69 | 96 |
| 2018 | 73 | 88 |
| 2019 | 73 | 106 |
| 2020 | 71 | 111 |
| 2021 | 74 | 101 |
| 2022 | 78 | 76 |
| 2023 | 50 | 91 |
| 2024 | 52 | 85 |
| 2025 | 49 | 57 |
| 2026 | 19 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/24211HepacivirusIndexing code881
- C12N 2770/24111FlavivirusIndexing code790
- C12N 2770/24311PestivirusIndexing code166
- C12N 2770/24022New viral proteins or individual genes, new structural or functional aspects ofIndexing code74
- C12N 2770/24034Use of virus or viral component as vaccineIndexing code41
- C12N 2770/24051Methods of production or purification of viral materialIndexing code12
- C12N 2770/24061Methods of inactivation or attenuationIndexing code7
- C12N 2770/24021Viruses as suchIndexing code5
All 15 subgroupsShow fewer
- C12N 2770/24023Virus like particles [vlp]Indexing code5
- C12N 2770/24041Use of virus, viral particle or viral elements as a vectorIndexing code5
- C12N 2770/24071Demonstrated in vivo effectIndexing code5
- C12N 2770/24031Uses of virus other than therapeutic or vaccineIndexing code3
- C12N 2770/24032Use of virus as therapeutic agent, other than vaccineIndexing code1
- C12N 2770/24033Use of viral protein as therapeutic agent other than vaccineIndexing code1
- C12N 2770/24088For redistributionIndexing code0
Recent patents
- Live-attenuated flaviviruses with heterologous antigens22 Sep 2026US 12,741,991 B2Katholieke Universiteit Leuven
- Compositions and methods for stabilizing flaviviruses with improved formulations15 Sep 2026US 12,734,230 B2Takeda Vaccines, Inc.
- Zika/dengue vaccine and application thereof2 Jun 2026US 12,642,846 B2Institute of Microbiology, Chinese Academy of Sciences
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Methods and compositions for the detection of host protein cleavage by group IV viral proteases21 Apr 2026US 12,607,633 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- High-yield genotype 1a, 2a and 3a hcv10 Sep 2026US 2026/0263580 A1Hvidovre Hospital
Most cited
By later US patents
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Recombinant infectious non-segmented negative strand RNA virus156US 6,033,886 A2000
- HCV immunoassays employing C domain antigens147US 5,350,671 AChiron Corporation · 1994
- Gas inlet for a plurality of reactant gases into reaction vessel142US 5,441,703 AAixtron SE · 1995